Lapatinib targeted therapy for HER2-positive breast cancer

Lapatinib, an anti-tumor drug developed by the British company GlaxoSmithKline, has become an important weapon in the treatment of advanced or metastatic HER2-positive breast cancer due to its unique tyrosine kinase inhibitory effect. Lapatinib, trade name Telisa, precisely targets and inhibits human epidermal growth factor receptor-1(ErbB1) and receptor -2 (ErbB2) activity, effectively blocking key signaling pathways for cancer cell growth.

The innovation of lapatinib lies in its dual mechanism of action, which targets HER2, a key protein that is often overexpressed in breast cancer, and its related ErbB1 receptor. These two receptors play central roles in the proliferation, differentiation, and migration of tumor cells. Lapatinib competitively binds to these receptors and significantly reduces their tyrosine kinase activity, thereby blocking cancer cells from receiving growth signals and achieving the purpose of inhibiting or killing tumor cells.

Especially for HER2 positive breast cancer patients, lapatinib has shown significant therapeutic effects. Such patients often face a higher risk of recurrence and poor prognosis, and the addition of lapatinib brings new hope to their treatment. Clinically, lapatinib is often used in combination with chemotherapy drugs such as capecitabine to enhance treatment response. This combination therapy not only extended the patient's survival period, but also significantly reduced the tumor size, alleviated pain and other related symptoms, and greatly improved the patient's quality of life.

The recommended daily dose of lapatinib is 1250 mg, which is recommended to be taken at least one hour before or one hour after a meal to ensure optimal absorption. When used in combination with capecitabine, there is a specific medication cycle schedule and medical advice must be strictly followed. Patients should pay close attention to possible side effects during medication, including gastrointestinal reactions (such as nausea, diarrhea), skin problems (such as dryness, rash), and respiratory symptoms (such as difficulty breathing). Long-term treatment also requires vigilance for the emergence of drug resistance, which requires doctors to continuously evaluate the effectiveness of treatment and consider adjusting treatment plans.

It is worth noting that the efficacy of lapatinib is highly dependent on the patient'sHER2 status. Therefore, it is crucial to conduct HER2 gene testing before treatment. Only when the patient is confirmed to be HER2 positive can lapatinib achieve its best efficacy. For patients who are HER2 negative, the drug may not be suitable, underscoring the importance of personalized treatment.

In summary, lapatinib can be used to target HER2Targeted therapeutic drugs for positive breast cancer provide patients with effective treatment options by precisely blocking cancer cell growth signals. Despite challenges such as drug resistance and side effects, its contribution to improving patient survival and quality of life cannot be ignored. With the deepening of research, the combined application of lapatinib and other treatments in the future, as well as the development of new targeted therapies, will further broaden the treatment prospects of breast cancer and bring more hope to patients.

xa0

Reference materials:https://go.drugbank.com/drugs/DB01259